Please login to the form below
IGAS
This page shows the latest IGAS news and features for those working in and with pharma, biotech and healthcare.
Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more
This is the second breakthrough therapy drug designation for OMS721, which gained the status last year for treatment of Immunoglobulin A (IgA) nephropathy, in which pivotal phase III trials recently begun.
Latest news
-
Rigel and Ultragenyx claim approvals for rare drugs
Rigel is also developing it for additional indications, including autoimmune haemolytic anaemia and IgA nephropathy.
-
Rigel shaken after fostamatinib misses phase III trial target
Estimates for peak sales are in the $300m-400m range. Fostamatinib is also in phase II trials for two other rare diseases - autoimmune haemolytic anaemia and IgA nephropathy.
-
Retrophin rockets away as rare disease trial hits targets
He added that after taking on the drug a decision had to be taken on developing it for FSG or another rare kidney disease called IgA nephropathy, as there was only
-
Firms at fault in fatal clinical trial, says French government
The IGAS launched the probe in January in the wake of the death of Guillaume Molinet, which occurred in a first-in-man trial at Biotrial's phase I trial facility ... It also vehemently contests the findings of the IGAS report, saying it failed to take
-
French government begins investigation into fatal Biotrial study
France's National Agency for the Safety of Medicines and Health Products (MSNA) and Inspectorate-General of Social Affairs (IGAS) are spearheading the investigation.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Hayward Medical Communications launch a new, eye-opening journal
Hayward is particularly pleased that the journal features regular columns from the International Glaucoma Association (IGA) and the Royal National Institute of Blind People (RNIB).
-
Hayward Medical Communications launch a new, eye-opening journal
Hayward is particularly pleased that the journal features regular columns from the International Glaucoma Association (IGA) and the Royal National Institute of Blind People (RNIB).
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
Subscribe to our email news alerts
- Brexit rebels win vote on European Medicines Agency alignment
- AstraZeneca joins Merck in Brexit stockpiling effort
- NHS England to Vertex: come clean on Orkambi offer
- Moving annual total (MAT)
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
CAN advertising
Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
